CD7 CAR-T cell therapy (Hebei Senlang Biotechnology)

N/A

Report date: 2025/11/26 20:00:44

Base Information

Drug NameCD7 CAR-T cell therapy (Hebei Senlang Biotechnology)
Drug Alias NameCD7-Specific CAR-T Cells (Senlang)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD7
TargetsT-cell antigen CD7
Therapy Area/IndicationsPrecursor T-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHebei Senlang Biological Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHebei Senlang Biological Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsPrecursor T-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A